Dr Shezad Malik Law Firm has offices based in Fort Worth and Dallas and represents people who have suffered catastrophic and serious personal injuries including wrongful death, caused by the negligence or recklessness of others. We specialize in Personal Injury trial litigation and focus our energy and efforts on those we represent.

Onglyza Heart Failure Injuries Lawsuits Centralized

Onglyza Heart Failure Injuries Lawsuits Centralized. Recently, the U.S. Judicial Panel on Multidistrict Litigation (JPML) has ordered that all filed federal Onglyza heart failure injuries lawsuits be consolidated and centralized as part of multidistrict litigation or MDL.

Type 2 diabetic patients who used Onglyza and developed heart problems allegedly caused by the diabetes drug will be consolidated in the U.S. District Court Eastern District of Kentucky, before U.S. District Judge Karen Caldwell.

What is an MDL?

MDL, or multidistrict litigation, is common in complex pharmaceutical and medical device product liability litigation, where a large number of individuals allege similar injuries following use of the same medication or medical device. The MDL process is designed to streamline the litigation process, reduce the time to trial and be a more efficient use of court resources since all of the plaintiffs and defendants are under one roof.

Onglyza Heart Failure Injuries Federal Litigation

There are about 100 personal injury and product liability lawsuits pending in the federal court system. All of the lawsuits have similar allegations that the manufacturer AstraZeneca failed to adequately warn about the potential heart failure side effects of Onglyza.

What is Onglyza?

Onglyza (Saxagliptin), made by Bristol-Myers Squibb and AstraZeneca, is used for the treatment of Type 2 diabetes. Onglyza belongs to a new class of diabetic drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors.

What are DiPeptidyl Peptidase 4 Inhibitors?

Dipeptidyl peptidase 4 inhibitors are oral antidiabetes medications that help control blood sugar levels in Type 2 diabetes patients. They block the enzyme dipeptidyl peptidase 4 and regulate the levels of insulin the body produces after a meal.

Dipeptidyl peptidase 4 inhibition results in increased activity of incretins, which blocks glucagon release. This leads to increased insulin release, slows gastric emptying and reduces blood sugar levels.

What is the problem with Onglyza?

Onglyza was cleared for sale by the FDA for treatment of type 2 diabetes in 2009, but over the last few years, many experts have expressed concern over heart safety, leading the FDA to require stronger label warnings about the increased risk of heart failure and other heart complications.

Plaintiffs blame AstraZeneca for the increased risk of heart failure, furthermore, they allege that the multinational pharmaceutical giant knew or should have known about the Onglyza heart risks for years, yet failed to adequately warn users and the doctors about the diabetes drug’s heart failure risks.


If you or a loved one has taken Onglyza and suffered heart failure and/or death, you may have a case for compensation against AstraZeneca. To learn more about your legal rights, call Dr. Shezad Malik Law Firm at 214-390-3189 for a free case review. Dr. Shezad Malik Law Firm is based in Dallas, Texas and is investigating and accepting Onglyza Heart Failure Injury cases nationwide.

Read more here

Texas Onglyza Heart Failure Lawsuit

Contact Information